Collecting Tumor Samples and Blood Biomarkers in Melanoma Patients
Official title: Molecular Characterisation of Serial Tumour Samples and Their Correlation With Circulating Biomarkers and Other Biospecimens Taken During the Clinical Course of Patients Receiving Treatment for Malignant Melanoma.
Run by The Christie NHS Foundation Trust · NCT04493723 · Data updated 2026-11-12
This study is collecting tumor and blood samples from people with advanced melanoma to see why some don’t respond to cancer treatments and to find clues that could help in the future.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | The Christie NHS Foundation Trust Academic / other |
| Locations | 1 site (Manchester) |
| Status | Recruiting |
| Started | November 14, 2018 |
| Main results expected | July 2034 |
| Study ends | July 2034 |
| Registry record updated | July 30, 2020 |
| Trial ID | NCT04493723 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 16 and over with locally advanced or metastatic melanoma who are undergoing treatment as part of their routine care.
✕Probably not a fit
Patients who are unable to provide informed consent or have significant bleeding disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect tumor biopsies and blood samples from patients with advanced melanoma to understand why some patients develop resistance to anti-cancer treatments. Participants will provide samples before, during, and after their treatment as part of their routine care. The study will analyze these samples to identify predictive biomarkers of treatment resistance and to characterize genetic changes associated with circulating tumor markers. Informed consent will be obtained from all participants, and they may also provide additional samples if they choose to do so.
Why it matters
Potential benefit: If successful, this study could lead to the development of predictive biomarkers that help tailor treatments for melanoma patients, improving their outcomes.
How similar studies have gone: Other studies have shown promise in using tumor biopsies and blood biomarkers to understand treatment resistance in cancer, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age of 16 years or more. 2. Patients must have given written informed consent. 3. Evidence of locally advanced or metastatic melanoma, i.e. stage III or IV disease. 4. Accessible tumour that can be safely biopsied using radiological or surgical techniques (if consenting to part A). 5. Full blood count and coagulation tests within acceptable parameters (if consenting to part A). Exclusion Criteria: 1. Inability to provide informed consent. 2. History of significant bleeding disorder (patients on anticoagulation are eligible if the anticoagulation can be safely managed to allow fresh tumour biopsies and blood sampling). 3. History of HIV, Hepatitis B/C or other transmissible human disease. 4. Any conditions where research biopsies or blood sampling may increase risk of complications for the patient and/or investigator, including high risk groups such as intravenous drug users.
Where it's running
-
The Christie
Manchester, United Kingdom Recruiting
Study contacts
- Principal investigator: Lorigan, Prof — University of Manchester
- Study coordinator: Gupta, Dr
- Email: avinash.gupta@christie.nhs.uk
- Phone: 0161 446 3472
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.